



Analysis of Global Hepatitis E Vaccine Development Status

Guest Editors:

Prof. Dr. María-Teresa Pérez-Gracia

Área de Microbiología,
Departamento de Farmacia,
Instituto de Ciencias Biomédicas,
Facultad de Ciencias de la Salud,
Universidad Cardenal Herrera-
CEU, CEU Universities, Avenida
Seminario s/n, 46113 Moncada,
Spain

Dr. Antonio Rivero-Juárez

Instituto Maimonides de
Investigación Biomédica de
Córdoba (IMIBIC), Hospital
Universitario Reina Sofía de
Córdoba, Universidad de
Córdoba, CIBER de
Enfermedades Infecciosas,
Cordoba, Spain

Deadline for manuscript
submissions:

closed (11 September 2022)

Message from the Guest Editors

Hepatitis E is a liver disease caused by the hepatitis E virus (HEV). In the vast majority of people, HEV infection results in a self-limited, acute illness. However, acute infection can become chronic in rare cases, primarily in people who have received solid-organ transplants. The human body is generally susceptible to HEV, and people of all ages can be infected. HEV is unique in that it has a different clinical and epidemiologic profile depending on where the infection is acquired. This can be attributed largely to the viral genotypes circulating in different parts of the world. Vaccination is the most direct and effective means of individual protection.

At present, there are few products in the pipeline of hepatitis E vaccine development, and research is mainly focused on recombinant protein vaccines and DNA vaccines. This Special Issue aims to gather works addressing all hepatitis E vaccine development information. This Special Issue will welcome all kinds of articles, e.g., reviews, short reports, hypotheses, research articles, opinions, and comments, on all hepatitis E vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com